AMGN Ticker Curator

FDA enforcement declares compounded tirzepatide/semaglutide as copies, caps tolerance at 4 Rx/month, bars 503B bulk use. ProRx halted production; now...

Cumulative ~$430M hit from $406M verdict (incl. $271.2M punitive to Regeneron for cholesterol monopoly) and $24.75M government settlement underscores persistent Repatha/PCSK9 antitrust overhangs, threatening FY26 ramps.

Goldman Sachs upgrades Amgen from Neutral to Buy with a $33 price target, viewing it as an attractive late-cycle consumer play.

Congressional insider move: Rep. Maria Elvira Salazar bought over $221K in Amgen on March 24.

• Performance context: Biotech giant delivered nearly...

• Canaccord Genuity initiates Hold on AMGN with $366 PT, first under new coverage.
• Bernstein maintains Hold via Courtney Breen, sets $335 PT.
• Hold consensus spans $31 PT gap, signaling balanced analyst views on valuation.

Amgen's Tepezza data outshines Viridian, sending rival Viridian shares plunging. This Q2 2026 readout sharpens AMGN's edge in the race.

AMGN investors beware: Repatha lawsuits target Amgen over serious side effects, with 2026 eligibility rules, settlement amounts, and claims process detailed. Monitor for potential legal and payout impacts.

The global obesity medicines market hit $66 billion in list price sales in 2025 per IQVIA's ForecastLink, forecast to rise to $92 billion in 2026-2030 outlook.

Legal and Regulatory Risks

• 🔥 ERISA Lawsuit: Amgen faces an ERISA suit over health plan tobacco surcharges, with a 48-page complaint filed by...

A Senate HELP Committee witness is elaborating on a prior call for wholesale change to the 340B program, proposing to replace current drug discounts with a subsidy program—a shift that could reshape pharma pricing dynamics.

Amgen shows 10% LTM revenue growth and 11.9% 3-year average, with 24.8% operating margins and no margin shock – key catalysts for a potential stock rally.

ChartMill delivers key TA on AMGN:

• Trend direction and chart patterns
• Support/resistance levels
• RSI, MACD, and volatility
  Ideal for spotting short-term trades.

Clinical development is a major driver of BsADC market growth, with a rapidly expanding pipeline across early, mid, and late stages. Vital signal for AMGN's bispecific oncology programs.

Amgen delivered 10% sales growth for 2025, fueled by a 46% non-GAAP operating margin and $8.1 billion free cash flow, showcasing broad growth amid manageable risks.

Amgen is hit with an ERISA suit from former employee Sanjay Sharma, who alleges paying unlawful tobacco surcharges to maintain health insurance coverage. The 48-page complaint underscores emerging legal risks in employee benefits practices.

AMGN's obesity drug pipeline strength is under scrutiny, while Enbrel biosimilar uptake rates demand monitoring—real-world switching informs revenue guidance, and quarterly earnings will reveal payer lump-sum trends.

Investor buzz is high: AMGN is among the most watched stocks on Zacks.com.

• Performance lag: +0.1% past month vs. S&P 500 +6.4%; biotech sector...

Antitrust Verdict

• 🔥 A jury verdict finds Amgen liable for antitrust violations, awarding Regeneron $407 million.

Earnings Preview

• ⚡...

Unlock full Amgen earnings call transcripts for current and past calls to evaluate stock performance and strategic direction.

Key expectations ahead of Apr. 30 release:

• Adjusted EPS of $4.75, down 3.1% YoY, but AMGN has beaten estimates for 4 straight quarters.
• Strong Q4...